 Michael Strong
Concepts (404)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 27 | 2025 | 363 | 5.960 |
Why?
| | Genome, Bacterial | 15 | 2024 | 150 | 3.880 |
Why?
| | Mycobacterium | 11 | 2023 | 111 | 3.600 |
Why?
| | Nontuberculous Mycobacteria | 16 | 2024 | 205 | 3.220 |
Why?
| | Mycobacterium tuberculosis | 19 | 2023 | 316 | 2.740 |
Why?
| | Mycobacterium abscessus | 12 | 2025 | 117 | 2.420 |
Why?
| | Whole Genome Sequencing | 5 | 2025 | 169 | 1.690 |
Why?
| | Mycobacterium Infections | 6 | 2021 | 62 | 1.570 |
Why?
| | Neurodegenerative Diseases | 8 | 2025 | 139 | 1.500 |
Why?
| | Cystic Fibrosis | 13 | 2025 | 1129 | 1.340 |
Why?
| | Tuberculosis | 8 | 2023 | 279 | 1.290 |
Why?
| | Frontotemporal Dementia | 4 | 2023 | 57 | 1.160 |
Why?
| | Genomics | 7 | 2021 | 810 | 1.140 |
Why?
| | Phylogeny | 14 | 2021 | 1005 | 1.040 |
Why?
| | Genotype | 6 | 2024 | 1862 | 0.970 |
Why?
| | Antitubercular Agents | 8 | 2023 | 200 | 0.950 |
Why?
| | Amyotrophic Lateral Sclerosis | 2 | 2017 | 97 | 0.910 |
Why?
| | Bacteriophages | 3 | 2022 | 106 | 0.870 |
Why?
| | Genome, Viral | 3 | 2021 | 223 | 0.870 |
Why?
| | Lung Diseases | 3 | 2022 | 793 | 0.850 |
Why?
| | Computational Biology | 9 | 2018 | 664 | 0.850 |
Why?
| | Methylobacterium | 1 | 2023 | 3 | 0.830 |
Why?
| | Sequence Analysis, DNA | 8 | 2022 | 817 | 0.800 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2022 | 544 | 0.780 |
Why?
| | Protein Domains | 1 | 2024 | 303 | 0.760 |
Why?
| | Herpesvirus 4, Human | 5 | 2016 | 165 | 0.760 |
Why?
| | Drug Resistance, Bacterial | 8 | 2024 | 189 | 0.740 |
Why?
| | Genetic Variation | 8 | 2021 | 994 | 0.730 |
Why?
| | Viral Nonstructural Proteins | 1 | 2021 | 67 | 0.690 |
Why?
| | Databases, Genetic | 3 | 2018 | 243 | 0.670 |
Why?
| | Lysogeny | 1 | 2020 | 5 | 0.670 |
Why?
| | Prophages | 1 | 2020 | 8 | 0.670 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 123 | 0.660 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 649 | 0.660 |
Why?
| | DNA-Binding Proteins | 5 | 2024 | 1478 | 0.640 |
Why?
| | Bacterial Proteins | 10 | 2016 | 910 | 0.620 |
Why?
| | Plasmids | 1 | 2020 | 365 | 0.620 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1968 | 0.620 |
Why?
| | Cross Infection | 4 | 2025 | 253 | 0.590 |
Why?
| | Viruses | 1 | 2021 | 163 | 0.590 |
Why?
| | Hawaii | 5 | 2023 | 38 | 0.590 |
Why?
| | Humans | 78 | 2025 | 140898 | 0.570 |
Why?
| | Mutation | 3 | 2021 | 3999 | 0.570 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2128 | 0.560 |
Why?
| | Soil Microbiology | 2 | 2020 | 214 | 0.560 |
Why?
| | Equipment Contamination | 2 | 2016 | 71 | 0.550 |
Why?
| | DNA, Bacterial | 5 | 2021 | 333 | 0.550 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 366 | 0.540 |
Why?
| | Tissue Adhesives | 1 | 2017 | 23 | 0.520 |
Why?
| | Dura Mater | 1 | 2017 | 34 | 0.510 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2017 | 67 | 0.490 |
Why?
| | Respiratory System | 1 | 2017 | 157 | 0.490 |
Why?
| | Research Personnel | 1 | 2018 | 177 | 0.480 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2021 | 344 | 0.480 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 78 | 0.470 |
Why?
| | Cardiac Surgical Procedures | 2 | 2019 | 587 | 0.470 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 321 | 0.470 |
Why?
| | Viral Matrix Proteins | 1 | 2015 | 30 | 0.470 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2015 | 18 | 0.470 |
Why?
| | Software | 5 | 2022 | 676 | 0.450 |
Why?
| | Databases, Nucleic Acid | 1 | 2014 | 38 | 0.440 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2015 | 120 | 0.440 |
Why?
| | Disease Outbreaks | 4 | 2025 | 418 | 0.440 |
Why?
| | Cerebrovascular Disorders | 2 | 2025 | 97 | 0.430 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2015 | 98 | 0.420 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 208 | 0.410 |
Why?
| | Stomach Neoplasms | 1 | 2015 | 118 | 0.410 |
Why?
| | Skin Diseases, Bacterial | 1 | 2013 | 21 | 0.410 |
Why?
| | Systems Biology | 1 | 2014 | 70 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2368 | 0.400 |
Why?
| | Microbiota | 1 | 2021 | 758 | 0.400 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2016 | 129 | 0.390 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 523 | 0.390 |
Why?
| | tau Proteins | 5 | 2025 | 95 | 0.380 |
Why?
| | Respiratory Tract Diseases | 1 | 2014 | 180 | 0.370 |
Why?
| | Ontario | 6 | 2025 | 95 | 0.350 |
Why?
| | Cognition Disorders | 1 | 2015 | 513 | 0.350 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 408 | 0.340 |
Why?
| | Molybdenum | 2 | 2021 | 10 | 0.340 |
Why?
| | Sputum | 6 | 2021 | 311 | 0.320 |
Why?
| | Metagenomics | 2 | 2021 | 181 | 0.320 |
Why?
| | Hydrogels | 1 | 2017 | 687 | 0.310 |
Why?
| | Protein Binding | 4 | 2024 | 2238 | 0.310 |
Why?
| | Alzheimer Disease | 3 | 2023 | 594 | 0.300 |
Why?
| | Physicians | 1 | 2018 | 928 | 0.300 |
Why?
| | Proteins | 3 | 2014 | 1013 | 0.300 |
Why?
| | Lung | 6 | 2023 | 4127 | 0.290 |
Why?
| | RNA, Viral | 2 | 2024 | 691 | 0.280 |
Why?
| | RNA | 2 | 2014 | 929 | 0.280 |
Why?
| | United States | 10 | 2022 | 15195 | 0.270 |
Why?
| | Proteomics | 4 | 2010 | 1136 | 0.270 |
Why?
| | Genes, Bacterial | 4 | 2017 | 165 | 0.260 |
Why?
| | Treatment Outcome | 4 | 2025 | 11125 | 0.260 |
Why?
| | Gene Expression Profiling | 9 | 2023 | 1761 | 0.250 |
Why?
| | Chromosome Mapping | 2 | 2023 | 504 | 0.240 |
Why?
| | Canada | 2 | 2018 | 419 | 0.240 |
Why?
| | Bacterial Typing Techniques | 2 | 2017 | 44 | 0.240 |
Why?
| | Cluster Analysis | 4 | 2014 | 516 | 0.230 |
Why?
| | Tuberculosis, Multidrug-Resistant | 3 | 2016 | 50 | 0.220 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 396 | 0.220 |
Why?
| | Evolution, Molecular | 2 | 2021 | 505 | 0.220 |
Why?
| | Soil | 3 | 2022 | 207 | 0.210 |
Why?
| | Virulence | 3 | 2020 | 267 | 0.210 |
Why?
| | Microvessels | 1 | 2025 | 86 | 0.210 |
Why?
| | DNA Repeat Expansion | 2 | 2014 | 12 | 0.210 |
Why?
| | Reference Standards | 1 | 2024 | 185 | 0.210 |
Why?
| | Gene Expression | 2 | 2021 | 1490 | 0.210 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2024 | 102 | 0.210 |
Why?
| | Immunity, Innate | 3 | 2021 | 852 | 0.210 |
Why?
| | Brain | 3 | 2025 | 2852 | 0.200 |
Why?
| | Self Concept | 1 | 2025 | 259 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 147 | 0.200 |
Why?
| | Multigene Family | 1 | 2003 | 202 | 0.200 |
Why?
| | Neuropsychological Tests | 3 | 2017 | 1089 | 0.200 |
Why?
| | Data Accuracy | 1 | 2023 | 63 | 0.200 |
Why?
| | Scoliosis | 1 | 2025 | 221 | 0.190 |
Why?
| | Transcriptome | 4 | 2023 | 1007 | 0.190 |
Why?
| | Gene Expression Regulation, Bacterial | 5 | 2023 | 321 | 0.190 |
Why?
| | Virus Replication | 2 | 2016 | 531 | 0.190 |
Why?
| | Spinal Fusion | 1 | 2025 | 258 | 0.190 |
Why?
| | Phosphoproteins | 1 | 2024 | 335 | 0.180 |
Why?
| | Protein Conformation, beta-Strand | 1 | 2021 | 18 | 0.180 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2021 | 19 | 0.180 |
Why?
| | Furin | 1 | 2021 | 14 | 0.180 |
Why?
| | Asia | 1 | 2021 | 68 | 0.180 |
Why?
| | Biomedical Research | 2 | 2018 | 680 | 0.180 |
Why?
| | Africa | 1 | 2021 | 115 | 0.180 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 111 | 0.180 |
Why?
| | Epidemiological Monitoring | 1 | 2021 | 65 | 0.170 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 73 | 0.170 |
Why?
| | Genome Size | 1 | 2020 | 11 | 0.170 |
Why?
| | Alanine | 1 | 2021 | 158 | 0.170 |
Why?
| | Transcription, Genetic | 6 | 2023 | 1485 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 150 | 0.170 |
Why?
| | Middle Aged | 14 | 2025 | 34487 | 0.170 |
Why?
| | Europe | 1 | 2021 | 406 | 0.170 |
Why?
| | Models, Molecular | 3 | 2016 | 1602 | 0.170 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 309 | 0.170 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 576 | 0.170 |
Why?
| | Bacteriological Techniques | 1 | 2021 | 66 | 0.170 |
Why?
| | Water Pollution | 1 | 2020 | 9 | 0.170 |
Why?
| | Metagenome | 1 | 2021 | 151 | 0.160 |
Why?
| | Water Quality | 1 | 2020 | 35 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2014 | 467 | 0.160 |
Why?
| | Antigens, Bacterial | 2 | 2014 | 125 | 0.160 |
Why?
| | Male | 20 | 2025 | 69893 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2022 | 247 | 0.150 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2020 | 81 | 0.150 |
Why?
| | Immune Evasion | 1 | 2020 | 63 | 0.150 |
Why?
| | Membrane Lipids | 1 | 2020 | 91 | 0.150 |
Why?
| | Bone and Bones | 1 | 2022 | 313 | 0.150 |
Why?
| | Adaptation, Physiological | 3 | 2023 | 562 | 0.150 |
Why?
| | Apolipoproteins E | 1 | 2019 | 91 | 0.150 |
Why?
| | Aged | 11 | 2025 | 24666 | 0.150 |
Why?
| | Pneumonia | 2 | 2023 | 656 | 0.150 |
Why?
| | Protein Conformation | 2 | 2016 | 939 | 0.150 |
Why?
| | Adult | 14 | 2025 | 39134 | 0.140 |
Why?
| | Phospholipids | 1 | 2020 | 221 | 0.140 |
Why?
| | Binding Sites | 1 | 2021 | 1315 | 0.140 |
Why?
| | Databases, Factual | 2 | 2021 | 1441 | 0.140 |
Why?
| | Host-Pathogen Interactions | 3 | 2016 | 370 | 0.140 |
Why?
| | Training Support | 1 | 2018 | 36 | 0.140 |
Why?
| | Mycolic Acids | 1 | 2017 | 7 | 0.140 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.140 |
Why?
| | Base Composition | 1 | 2017 | 79 | 0.140 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2920 | 0.130 |
Why?
| | Virus Diseases | 1 | 2020 | 215 | 0.130 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 62 | 0.130 |
Why?
| | Oregon | 1 | 2017 | 78 | 0.130 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 99 | 0.130 |
Why?
| | Valsalva Maneuver | 1 | 2017 | 10 | 0.130 |
Why?
| | Disease | 1 | 2018 | 99 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1856 | 0.130 |
Why?
| | Water Supply | 1 | 2017 | 86 | 0.130 |
Why?
| | Surgical Equipment | 1 | 2016 | 10 | 0.130 |
Why?
| | Sensation Disorders | 1 | 2017 | 39 | 0.130 |
Why?
| | Brazil | 2 | 2014 | 169 | 0.130 |
Why?
| | DNA Gyrase | 1 | 2016 | 12 | 0.120 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 46 | 0.120 |
Why?
| | Fluoroquinolones | 1 | 2016 | 43 | 0.120 |
Why?
| | Web Browser | 1 | 2015 | 13 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 268 | 0.120 |
Why?
| | Gene Ontology | 1 | 2015 | 52 | 0.120 |
Why?
| | Catalase | 1 | 2016 | 134 | 0.120 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2015 | 25 | 0.120 |
Why?
| | Female | 16 | 2025 | 75540 | 0.120 |
Why?
| | Isoniazid | 1 | 2016 | 61 | 0.120 |
Why?
| | Language Disorders | 1 | 2015 | 30 | 0.120 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 95 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 746 | 0.120 |
Why?
| | Social Perception | 1 | 2017 | 105 | 0.120 |
Why?
| | Mentors | 1 | 2018 | 212 | 0.120 |
Why?
| | Rifampin | 1 | 2016 | 80 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 232 | 0.120 |
Why?
| | Mouth Mucosa | 1 | 2016 | 90 | 0.120 |
Why?
| | Bacterial Toxins | 1 | 2016 | 104 | 0.120 |
Why?
| | Octamer Transcription Factors | 1 | 2015 | 3 | 0.120 |
Why?
| | Housing | 1 | 2016 | 146 | 0.120 |
Why?
| | Nuclear Matrix-Associated Proteins | 1 | 2015 | 7 | 0.120 |
Why?
| | Genes, Viral | 1 | 2015 | 92 | 0.120 |
Why?
| | Cohort Studies | 6 | 2025 | 5789 | 0.120 |
Why?
| | Virus Activation | 1 | 2016 | 86 | 0.120 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 197 | 0.110 |
Why?
| | Tumor Escape | 1 | 2015 | 47 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 545 | 0.110 |
Why?
| | Data Mining | 1 | 2016 | 115 | 0.110 |
Why?
| | Herpesviridae | 1 | 2014 | 22 | 0.110 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 99 | 0.110 |
Why?
| | Education, Medical | 1 | 2018 | 268 | 0.110 |
Why?
| | Viral Core Proteins | 1 | 2014 | 22 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2016 | 172 | 0.110 |
Why?
| | Retroviridae | 1 | 2014 | 103 | 0.110 |
Why?
| | Neuroimaging | 1 | 2017 | 279 | 0.110 |
Why?
| | Tuberculosis Vaccines | 1 | 2014 | 5 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2006 | 288 | 0.110 |
Why?
| | Colorado | 5 | 2024 | 4597 | 0.110 |
Why?
| | Biofilms | 1 | 2016 | 272 | 0.100 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7899 | 0.100 |
Why?
| | Postural Balance | 1 | 2017 | 237 | 0.100 |
Why?
| | RNA, Untranslated | 1 | 2015 | 124 | 0.100 |
Why?
| | Language | 1 | 2017 | 309 | 0.100 |
Why?
| | Operon | 2 | 2003 | 68 | 0.100 |
Why?
| | Biomarkers | 3 | 2025 | 4175 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3724 | 0.100 |
Why?
| | Extracellular Vesicles | 1 | 2016 | 153 | 0.100 |
Why?
| | Survival Analysis | 1 | 2017 | 1320 | 0.100 |
Why?
| | Brain Concussion | 1 | 2021 | 588 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2016 | 857 | 0.100 |
Why?
| | Heterozygote | 1 | 2014 | 308 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2003 | 238 | 0.100 |
Why?
| | Lymphoma | 1 | 2014 | 228 | 0.100 |
Why?
| | Galectins | 1 | 2013 | 27 | 0.100 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2020 | 658 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5645 | 0.100 |
Why?
| | Hepacivirus | 1 | 2014 | 238 | 0.100 |
Why?
| | Phenotype | 3 | 2016 | 3172 | 0.100 |
Why?
| | Virulence Factors | 1 | 2014 | 162 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1491 | 0.090 |
Why?
| | Epidemics | 1 | 2013 | 92 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2014 | 375 | 0.090 |
Why?
| | Motor Activity | 1 | 2017 | 718 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2025 | 234 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 148 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2082 | 0.090 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 447 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 447 | 0.090 |
Why?
| | Young Adult | 5 | 2025 | 13646 | 0.090 |
Why?
| | DNA, Viral | 1 | 2012 | 363 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2014 | 605 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5194 | 0.080 |
Why?
| | Base Sequence | 1 | 2013 | 2169 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3578 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 5895 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2016 | 1113 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2023 | 425 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 6944 | 0.080 |
Why?
| | MicroRNAs | 1 | 2016 | 691 | 0.080 |
Why?
| | Species Specificity | 2 | 2020 | 577 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2021 | 415 | 0.070 |
Why?
| | Signal Transduction | 2 | 2016 | 5148 | 0.070 |
Why?
| | Public Health | 1 | 2012 | 554 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2898 | 0.070 |
Why?
| | Cell Wall | 2 | 2006 | 60 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2604 | 0.060 |
Why?
| | Mice | 5 | 2023 | 18057 | 0.060 |
Why?
| | Treatment Failure | 2 | 2021 | 353 | 0.060 |
Why?
| | Uganda | 2 | 2016 | 86 | 0.060 |
Why?
| | Solubility | 1 | 2006 | 244 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2023 | 4407 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2006 | 532 | 0.060 |
Why?
| | Diffusion Tensor Imaging | 1 | 2025 | 75 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 485 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 112 | 0.050 |
Why?
| | Atrophy | 1 | 2025 | 196 | 0.050 |
Why?
| | Protein Kinases | 2 | 2016 | 308 | 0.050 |
Why?
| | Arizona | 1 | 2024 | 81 | 0.050 |
Why?
| | C9orf72 Protein | 2 | 2014 | 12 | 0.050 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2003 | 7 | 0.050 |
Why?
| | Iron | 2 | 2022 | 323 | 0.050 |
Why?
| | Galactans | 1 | 2003 | 5 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 757 | 0.050 |
Why?
| | Mexico | 1 | 2024 | 229 | 0.050 |
Why?
| | Genome | 1 | 2006 | 302 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10430 | 0.050 |
Why?
| | Dust | 1 | 2023 | 99 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2014 | 224 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3336 | 0.050 |
Why?
| | Animals | 6 | 2023 | 37579 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 187 | 0.050 |
Why?
| | Proteome | 2 | 2006 | 483 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 87 | 0.050 |
Why?
| | Oxides | 1 | 2022 | 50 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 746 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2025 | 16315 | 0.050 |
Why?
| | Clarithromycin | 1 | 2021 | 23 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 2967 | 0.040 |
Why?
| | Armadillos | 1 | 2021 | 2 | 0.040 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 9 | 0.040 |
Why?
| | Macrolides | 1 | 2021 | 68 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 267 | 0.040 |
Why?
| | Cell Membrane | 2 | 2020 | 720 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 179 | 0.040 |
Why?
| | Adolescent | 4 | 2025 | 22027 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1038 | 0.040 |
Why?
| | Smokers | 1 | 2021 | 142 | 0.040 |
Why?
| | Bone Marrow | 1 | 2022 | 301 | 0.040 |
Why?
| | Bioreactors | 1 | 2021 | 48 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 91 | 0.040 |
Why?
| | Spine | 1 | 2022 | 180 | 0.040 |
Why?
| | Water | 1 | 2023 | 466 | 0.040 |
Why?
| | Macrophages | 2 | 2020 | 1559 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 27 | 0.040 |
Why?
| | THP-1 Cells | 1 | 2020 | 19 | 0.040 |
Why?
| | Cathelicidins | 1 | 2020 | 41 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 45 | 0.040 |
Why?
| | Genetics, Population | 1 | 2021 | 208 | 0.040 |
Why?
| | Apolipoprotein E4 | 1 | 2019 | 38 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 689 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2879 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 381 | 0.040 |
Why?
| | Age Factors | 1 | 2025 | 3278 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 699 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2016 | 2822 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2021 | 515 | 0.030 |
Why?
| | Child | 3 | 2025 | 22313 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2791 | 0.030 |
Why?
| | Membrane Proteins | 2 | 2014 | 1156 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2012 | 2917 | 0.030 |
Why?
| | Gambia | 1 | 2016 | 8 | 0.030 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 395 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 694 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 949 | 0.030 |
Why?
| | Regulon | 1 | 2016 | 36 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2014 | 3487 | 0.030 |
Why?
| | Nitrogen Oxides | 1 | 2016 | 54 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 97 | 0.030 |
Why?
| | India | 1 | 2016 | 208 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 432 | 0.030 |
Why?
| | Palatine Tonsil | 1 | 2016 | 55 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 102 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2016 | 156 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 835 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1220 | 0.030 |
Why?
| | Replication Origin | 1 | 2015 | 21 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 189 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2780 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 179 | 0.030 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 68 | 0.030 |
Why?
| | Ataxins | 1 | 2014 | 4 | 0.030 |
Why?
| | Survival of Motor Neuron 2 Protein | 1 | 2014 | 5 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 36 | 0.030 |
Why?
| | Virus Integration | 1 | 2014 | 69 | 0.030 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2016 | 340 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2014 | 16 | 0.030 |
Why?
| | Motor Neuron Disease | 1 | 2014 | 21 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 88 | 0.030 |
Why?
| | Saliva | 1 | 2016 | 245 | 0.030 |
Why?
| | Accidental Falls | 1 | 2017 | 213 | 0.030 |
Why?
| | Extracellular Space | 1 | 2014 | 129 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1496 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2014 | 171 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 325 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 589 | 0.030 |
Why?
| | Burkitt Lymphoma | 1 | 2014 | 63 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 98 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 131 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 737 | 0.020 |
Why?
| | Muromegalovirus | 1 | 2013 | 23 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 30 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1052 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2014 | 327 | 0.020 |
Why?
| | United Kingdom | 1 | 2014 | 319 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1310 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2017 | 578 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2016 | 398 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2013 | 95 | 0.020 |
Why?
| | Interferons | 1 | 2014 | 195 | 0.020 |
Why?
| | Interleukin-15 | 1 | 2013 | 100 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2013 | 123 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 388 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 198 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 310 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 389 | 0.020 |
Why?
| | Hepatitis C | 1 | 2014 | 250 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7749 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 146 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 463 | 0.020 |
Why?
| | NF-kappa B | 1 | 2014 | 690 | 0.020 |
Why?
| | Viral Proteins | 1 | 2012 | 369 | 0.020 |
Why?
| | Hypoxia | 1 | 2016 | 1164 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1231 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2152 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1726 | 0.020 |
Why?
| | Phosphorylation | 1 | 2010 | 1758 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2013 | 3064 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4199 | 0.010 |
Why?
| | Vaccination | 1 | 2014 | 1467 | 0.010 |
Why?
| | Biological Transport | 1 | 2006 | 409 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5931 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 239 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 856 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2006 | 525 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 493 | 0.010 |
Why?
|
|
Strong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|